Satake, Hironaga; Kato, Takeshi; Oba, Koji; Kotaka, Masahito; Kagawa, Yoshinori; Yasui, Hisateru; Nakamura, Masato; Watanabe, Takanori; Matsumoto, Toshihiko; Kii, Takayuki; Terazawa, Tetsuji; Makiyama, Akitaka; Takano, Nao; Yokota, Mitsuru; Okita, Yoshihiro; Matoba, Koreatsu; Hasegawa, Hiroko; Tsuji, Akihito; Komatsu, Yoshito; Yoshino, Takayuki; Yamazaki, Kentaro; Mishima, Hideyuki; Oki, Eiji; Nagata, Naoki; Sakamoto, Junichi published an article in 2020, the title of the article was Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).Related Products of 65-71-4 And the article contains the following content:
A biweekly TAS-102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS-102 plus BEV combination. Biweekly TAS-102 plus BEV combination could reduce unnecessary dose reduction of TAS-102, maintain higher doses, and possibly be effective even in cases without chemotherapy-induced neutropenia (CIN). The prespecified subgroup anal. of this study showed an obvious association between CIN within the first two cycles and prognosis of biweekly TAS-102 plus BEV. TAS-102 (trifluridine/tipiracil) plus bevacizumab (BEV) combination therapy has shown promising activity in patients with metastatic colorectal cancer (mCRC). However, the previously reported dose and schedule for the TAS-102 (70 mg/m2/day on days 1-5 and 8-12, every 4 wk) plus BEV (5 mg/kg on day 1, every 2 wk) regimen is complicated by severe hematol. toxicities and difficult administration schedules. Here, we evaluated the efficacy and safety of a more convenient biweekly TAS-102 plus BEV combination. Patients with mCRC who were refractory or intolerant to standard chemotherapies were enrolled. Patients received biweekly TAS-102 (twice daily on days 1-5, every 2 wk) with BEV (5mg/kg on day 1, every 2 wk). The primary endpoint was progression-free survival rate at 16 wk (16-w PFS rate). From Oct. 2017 to Jan. 2018, 46 patients were enrolled. The recommended phase II dose was determined to be TAS-102 (70 mg/m2/day). Of the 44 eligible patients, the 16-w PFS rate was 40.9% (95% confidence interval, 26.3%-56.8%), and the null hypothesis was rejected (p < .0001). Median progression-free survival (PFS) and overall survival were 4.29 mo and 10.86 mo, resp. Disease control rate was 59.1%. Common grade 3 or higher adverse events were hypertension (40.9%), neutropenia (15.9%), and leucopenia (15.9%). Biweekly TAS-102 plus BEV showed promising antitumor activity with safety. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Related Products of 65-71-4
The Article related to bevacizumab human metastatic colorectal cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Related Products of 65-71-4
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia